Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep1025 | Hot topics (including COVID-19) | ECE2020

Medications used by individuals with fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study

C. Hsiao Edward , Al Mukaddam Mona , Baujat Geneviève , De Cunto Carmen , Keen Richard , J Pignolo Robert , Harnett Kathleen , Marino Rose , Kaplan Frederick S

Background: FOP is an ultra-rare genetic disorder characterised by episodic progressive heterotopic ossification (HO) and flare-ups, causing cumulative disability and early death. FOP is diagnosed and managed by multiple specialists, including endocrinologists. There are no established disease-modifying therapies to prevent HO in FOP. Treatment guidelines for symptomatic relief of FOP have recently been published by the International Clinical Council on FOP (ICC).1<...